Jaguar Animal Health (NASDAQ:JAGX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Jaguar Animal Health (NASDAQ:JAGX) to a sell rating in a research note released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Jaguar Animal Health has a consensus rating of “Sell”.

Jaguar Animal Health Trading Down 3.1%

Shares of NASDAQ JAGX opened at $4.64 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.40 and a current ratio of 0.69. The business’s 50 day moving average price is $9.37 and its 200-day moving average price is $57.76. Jaguar Animal Health has a fifty-two week low of $2.35 and a fifty-two week high of $1,260.00. The company has a market cap of $1.58 million, a price-to-earnings ratio of -0.00 and a beta of -0.11.

Jaguar Animal Health (NASDAQ:JAGX) last announced its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($782.25) by $766.55. The firm had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $4.24 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and marketing products for gastrointestinal disorders in companion and production animals. Its research is centered on plant-based medicines, including products derived from the red-barked croton tree, Croton lechleri, traditionally used in South America.

The company’s lead animal health product is Canalevia-CA1, a prescription drug containing crofelemer that received conditional approval from the U.S.